文献速递心境障碍会诊联络精神医学

免疫调节药物对抑郁症状的影响:炎症性疾病随机安慰剂对照试验的汇总分析

Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders.
PubMed 文献 · Mol Psychiatry · 2019-08-19

该汇总分析整合18项随机安慰剂对照试验的个体数据(N=10,743),评估免疫调节药物对炎症性疾病共病抑郁症状的疗效。高抑郁层患者核心抑郁症状改善 modest 但显著(SMD=0.29,95%CI 0.12-0.45),抗IL-6和抗IL-12/23抗体效果较大。控制躯体健康变化后部分效应减弱,但抗IL-12/23仍显著。

要点

  • 高抑郁层患者核心抑郁症状改善SMD=0.29(95%CI 0.12-0.45)。
  • 抗IL-6抗体SMD=0.8(95%CI 0.20-1.41),抗IL-12/23抗体SMD=0.48(95%CI 0.26-0.70)。
  • 调整躯体健康后平均效应减弱至SMD=0.20(95%CI 0.06-0.35)。

核心结论

  • 免疫调节药物对炎症性疾病共病抑郁症状有 modest 但显著的改善作用,部分效应不完全由躯体健康变化解释。

研究设计与样本

  • 汇总分析18项Janssen或GlaxoSmithKline开展的随机安慰剂对照试验,涵盖9种疾病,N=10,743。
  • 核心抑郁症状用SF-36或HADS测量,按基线评分分为高抑郁层(N=1921)和低抑郁层。
  • 评估4-16周治疗前后安慰剂对照变化,使用标准化均数差(SMD),并分析7种机制亚组。

主要发现

  • 高抑郁层患者核心抑郁症状SMD=0.29(95%CI 0.12-0.45),SF-36心理健康和活力指标也有改善。
  • 抗IL-6抗体SMD=0.8(95%CI 0.20-1.41),抗IL-12/23抗体SMD=0.48(95%CI 0.26-0.70),效果大于其他药物类别。
  • 调整躯体健康结局后,平均治疗效应SMD=0.20(95%CI 0.06-0.35),心理健康和活力效应减弱更明显。
  • 控制躯体治疗反应后,抗IL-12/23效应仍显著,抗IL-6抗体变为趋势。

关键数值与推荐

  • 高抑郁层核心抑郁症状SMD=0.29(95%CI 0.12-0.45)。
  • 抗IL-6抗体SMD=0.8(95%CI 0.20-1.41)。
  • 抗IL-12/23抗体SMD=0.48(95%CI 0.26-0.70)。
  • 调整躯体健康后平均效应SMD=0.20(95%CI 0.06-0.35)。

临床怎么用

  • 对炎症性疾病共病抑郁症状患者,免疫调节药物可能带来额外心境获益。
  • 抗IL-6和抗IL-12/23抗体可能对抑郁症状效果更突出,但需结合躯体疾病治疗。
  • 临床评估抑郁改善时需考虑躯体健康变化对量表评分的部分影响。

局限性

  • 原文未报告纳入试验的具体偏倚风险、异质性或亚组样本量细节。
  • 抑郁症状为次要结局,使用SF-36或HADS而非专用抑郁量表。
  • 高抑郁层定义基于基线评分分层,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activation of the innate immune system is commonly associated with depression. Immunomodulatory drugs may have efficacy for depressive symptoms that are co-morbidly associated with inflammatory disorders. We report a large-scale re-analysis by standardized procedures (mega-analysis) of patient-level data combined from 18 randomized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders (N = 10,743 participants). Core depressive symptoms (low mood, anhedonia) were measured by the Short Form Survey (SF-36) or the Hospital Anxiety and Depression Scale (HADS), and participants were stratified into high (N = 1921) versus low-depressive strata based on baseline ratings. Placebo-controlled change from baseline after 4-16 weeks of treatment was estimated by the standardized mean difference (SMD) over all trials and for each subgroup of trials targeting one of 7 mechanisms (IL-6, TNF-α, IL-12/23, CD20, COX2, BLγS, p38/MAPK14). Patients in the high depressive stratum showed modest but significant effects on core depressive symptoms (SMD = 0.29, 95% CI [0.12-0.45]) and related SF-36 measures of mental health and vitality. Anti-IL-6 antibodies (SMD = 0.8, 95% CI [0.20-1.41]) and an anti-IL-12/23 antibody (SMD = 0.48, 95% CI [0.26-0.70]) had larger effects on depressive symptoms than other drug classes. Adjustments for physical health outcome marginally attenuated the average treatment effect on depressive symptoms (SMD = 0.20, 95% CI: 0.06-0.35), but more strongly attenuated effects on mental health and vitality. Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment. Novel immune-therapeutics can produce antidepressant effects in depressed patients with primary inflammatory disorders that are not entirely explained by treatment-related changes in physical health.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wittenberg GM, Stylianou A, Zhang Y, et al. Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry. 2019. PMID: 31427751. doi:10.1038/s41380-019-0471-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。